In short
Clinical trials are studying Luspatercept in people with blood disorders that cause anemia, or low red blood cell levels. These studies look at safety, benefit, dose, and blood transfusion needs in adults, children, and adolescents with conditions such as thalassemia, myelodysplastic syndromes, and myelofibrosis.
Key points
- Luspatercept is being studied in several blood disorders that cause anemia, especially thalassemia, myelodysplastic syndromes, and myelofibrosis. The trials include adults, children, and adolescents, and they test both people who need transfusions and people who do not. Most studies are Phase 2 or Phase 3, with one Phase 1 dose-finding study and one low-intervention study. The main goals are to see whether Luspatercept can reduce transfusion needs, improve hemoglobin, and provide long-term safety data. Some trials also measure special outcomes such as brain oxygen use, pharmacokinetics, and response in specific MDS groups like del5q or ring sideroblasts.
Trial overview
These studies investigate Luspatercept in people with different causes of anemia, which means low red blood cell levels. The trials are authorised and include interventional studies, where participants receive a study treatment and researchers measure the results.
The source data shows studies in beta-thalassemia, alpha-thalassemia, myelodysplastic syndromes, myelofibrosis, and rare inherited anemias. Some studies compare Luspatercept with placebo or with other anemia treatments, while others are single-arm studies, meaning everyone in the study gets the same study treatment.3
Blood disorders studied
Thalassemia is studied in both adults and younger patients. One trial focuses on non-transfusion dependent beta-thalassemia and asks whether treatment can improve brain oxygen use after hemoglobin rises by at least 1 g/dL. Another Phase 2 study includes pediatric participants with beta-thalassemia and looks at dose selection and pharmacokinetics, which is how the body handles the study drug.
Myelodysplastic syndrome (MDS) is another major area of study. Several trials focus on lower-risk MDS, including people with ring sideroblasts, del5q, or no ring sideroblasts, and many of these participants either need red blood cell transfusions or do not need them.3
Myelofibrosis is also studied, including people with MPN-associated myelofibrosis who need transfusions and are on JAK2 inhibitor therapy. One study also follows people who have already taken part in earlier Luspatercept trials to learn about long-term safety.
One trial studies rare inherited anemias, and another focuses on alpha-thalassemia in adults and adolescents. In that alpha-thalassemia study, adult and adolescent groups have different goals, with adults mainly assessed for erythroid response and adolescents studied for safe and tolerable dose selection.
Who can join these studies
Each trial has its own entry rules, but the source data gives some clear patterns. Some studies include only adults, such as the myelofibrosis and many MDS trials, while others include children or adolescents, such as the beta-thalassemia and alpha-thalassemia studies.
Several MDS studies are for people who are erythropoiesis-stimulating agent (ESA) naive, which means they have not used this type of anemia treatment before. Other studies include people who are refractory, intolerant, or ineligible for prior ESA treatment, meaning the earlier treatment did not work, caused problems, or could not be used.
Some trials focus on people who need red blood cell transfusions, while others focus on people who do not need transfusions. This is important because the studies are trying to see whether Luspatercept can reduce transfusion burden, improve hemoglobin, or both.
Trial phases and study designs
The source data includes Phase 1, Phase 2, Phase 3, and Phase 3b studies, plus one low-intervention study. Phase 1 studies usually help find the best dose and check early safety, while Phase 2 and Phase 3 studies test how well the treatment works and continue safety monitoring.
One study is a randomized Phase I/II multicenter trial in lower-risk MDS without ring sideroblasts, and it has a dose-finding part and a later comparison part. Another is an open-label, single-arm study, which means both researchers and participants know what treatment is given and there is no comparison group.
Some Phase 3 trials compare Luspatercept with other treatments such as epoetin alfa, while others compare it with placebo in specific disease groups. There is also a rollover Phase 3b study that follows people who already joined earlier Luspatercept trials so researchers can learn more about long-term safety.
Main endpoints and what they measure
The main endpoint in many studies is red blood cell transfusion independence (RBC-TI), which means a person goes for a set period without needing transfusions. Different trials use different time frames, such as 8 weeks, 12 weeks, or a continuous 16-week interval, so the exact definition changes from study to study.
Some studies measure a rise in hemoglobin, often by at least 1.0 g/dL or 1.5 g/dL, because this shows improvement in anemia. In the alpha-thalassemia study, adult cohorts are measured by either lower transfusion burden or a rise in hemoglobin without transfusions, while adolescent cohorts are also checked for dose-limiting toxicities, PK, and adverse events.
One thalassemia study uses MRI-based measurement of cerebral metabolic rate of oxygen (CMRO2), which means how much oxygen the brain uses. That study asks whether correcting anemia with Luspatercept can improve brain oxygenation in non-transfusion dependent beta-thalassemia.
In the long-term safety study, the endpoints include adverse events, progression to high or very high-risk MDS, progression to acute myeloid leukemia in MDS and myelofibrosis, and development of other malignancies or premalignancies. These outcomes show that the study is not only checking benefit, but also watching for disease worsening over time.
Special populations and specific trial goals
Several studies are designed for very specific patient groups, which helps researchers answer focused questions. For example, the del5q MDS study includes people with very low, low, or intermediate-risk disease who are refractory, resistant, intolerant, or ineligible to earlier treatments and who need transfusions.
The lower-risk MDS study comparing Luspatercept with epoetin alfa looks at people who have not taken ESA treatment before and need transfusions. Another lower-risk MDS study without ring sideroblasts looks at whether combining Luspatercept with EPO may improve response compared with Luspatercept alone.
The myelofibrosis study with momelotinib and Luspatercept is testing a combination approach in transfusion-dependent disease, with the main goal of transfusion independence by Week 24. This is important because it shows the research is also looking at combination treatment, not only Luspatercept alone.
The rare inherited anemia study includes patient groups named in the source as CSA, CDA, and NTD-DBA, and it measures whether transfusion burden falls or hemoglobin rises over 12 weeks. The source summary says this study looks for either transfusion independence, a major reduction in transfusions, or a meaningful hemoglobin increase.
Safety and long-term follow-up
Safety is an important part of nearly every trial in the source data. Some studies measure adverse events, which are unwanted medical problems that happen during the trial, and some also track serious outcomes such as disease progression or new cancers.
The pediatric alpha-thalassemia study includes specific safety checks such as dose-limiting toxicities and the frequency, severity, and seriousness of adverse events. This helps researchers decide whether the dose is safe and tolerable for younger participants.
The rollover Phase 3b study is especially important because it follows people after earlier Luspatercept trials and looks at long-term safety across diseases such as MDS, beta-thalassemia, and myelofibrosis. This kind of follow-up helps researchers understand what happens with longer use in trial participants.